Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Eli Lilly is a core holding in the Invictus Origin High-Alpha Black Swan Portfolio because it's robust, resilient, and fits perfectly in my antifragile capital allocation strategy.

Eli Lilly announced an update on its Phase 3 clinical study testing Mirikizumab for pediatric Crohn’s disease, showing real ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I initiate a Buy rating on LLY stock.

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.

Study Overview: Eli Lilly and Company is conducting a clinical study titled ‘Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

India’s anti-obesity drug market is seeing a sharp escalation in competition, as global pharmaceutical majors Novo Nordisk and Eli Lilly accelerate their efforts to capture share in the chronic ...